Identical pattern perhaps, but Cytodyn is hardly i
Post# of 148260
Therefore, we may not see the slow trickle downwards. People are starting to wise-up about Leronlimab’s epic potential, we’re seeing more publicity (WSJ), we’ve got the Long Hauler trial rolling, and CD12 right around the corner. Who knows if we get a BLA or NASDAQ surprise in the very near future.
Point being, we just could as easily see a steady ascent the next 30 days...